Maghfour Jalal, Sivesind Torunn Elise, Dellavalle Robert Paul, Dunnick Cory
Department of Dermatology, Henry Ford Hospital, Detroit, MI, United States.
Department of Dermatology, University of Colorado School of Medicine, Aurora, CO, United States.
JMIR Dermatol. 2021 Oct 1;4(2):e27869. doi: 10.2196/27869.
Although there has been an increase in the number of randomized controlled trials evaluating treatment efficacy for hidradenitis suppurativa (HS), instrument measurements of disease severity and quality of life (QoL) are varied, making the compilation of data and comparisons between studies a challenge for clinicians.
We aimed to perform a systematic literature search to examine the recent trends in the use of disease severity and QoL outcome instruments in randomized controlled trials that have been conducted on patients with HS.
A scoping review was conducted in February 2021. The PubMed, Embase, Web of Science, and Cochrane databases were used to identify all articles published from January 1964 to February 2021. In total, 41 articles were included in this systematic review.
The HS Clinical Response (HiSCR) score (18/41, 44%) was the most commonly used instrument for disease severity, followed by the Sartorius and Modified Sartorius scales (combined: 16/41, 39%). The Dermatology Life Quality Index (18/41, 44%) and visual analogue pain scales (12/41, 29%) were the most commonly used QoL outcome instruments in HS research.
Randomized controlled trials conducted from 2013 onward commonly used the validated HiSCR score, while older studies were more heterogeneous and less likely to use a validated scale. A few (6/18, 33%) QoL measures were validated instruments but were not specific to HS; therefore, they may not be representative of all factors that impact patients with HS.
National Institute of Health Research PROSPERO CRD42020209582; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020209582.
尽管评估化脓性汗腺炎（HS）治疗效果的随机对照试验数量有所增加，但疾病严重程度和生活质量（QoL）的仪器测量方法各不相同，这使得临床医生在汇总数据和进行研究间比较时面临挑战。
我们旨在进行系统的文献检索，以研究针对HS患者开展的随机对照试验中疾病严重程度和QoL结局指标的使用最新趋势。
2021年2月进行了一项范围综述。使用PubMed、Embase、科学网和Cochrane数据库来识别1964年1月至2021年2月发表的所有文章。本系统综述共纳入41篇文章。
HS临床反应（HiSCR）评分（18/41，44%）是最常用的疾病严重程度评估指标，其次是Sartorius量表和改良Sartorius量表（合计：16/41，39%）。皮肤病生活质量指数（18/41，44%）和视觉模拟疼痛量表（12/41，29%）是HS研究中最常用的QoL结局指标。
2013年以后开展的随机对照试验通常使用经过验证的HiSCR评分，而早期研究的异质性更大，使用经过验证量表的可能性较小。少数（6/18，33%）QoL测量方法是经过验证的指标，但并非HS特有的；因此，它们可能无法代表影响HS患者的所有因素。
英国国家卫生研究院PROSPERO CRD42020209582；https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020209582 。
